A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors.

doi:10.1158/1078-0432.CCR-24-1867

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 6 Jan 2025

Cote Gregory M, Kochupurakkal Bose S, Do Khanh, Bullock Andrea, Cheng Michael L, Muzikansky Alona, McLoughlin Daniel E, Cleary James M, Gao Xin, Parikh Aparna, Park Jong Chul, Weekes Colin D, Yeku Oladapo, Zou Lee, Shapiro Geoffrey I

Abstract excerpt

PURPOSE: Preclinical studies have identified molecular correlates of sensitivity to ATR inhibition. This translational study was designed to test the ATR inhibitor berzosertib in patients with advanced solid tumors carrying alterations in ATRX, ataxia-telangiectasia-mutated (ATM), genes conferring replication stress (RS), or SDH. PATIENTS AND METHODS: Patients were recruited to four cohorts: T1: ATRX-mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoxazoles

Share to Neoplasms

Share to Nuclear Proteins

Share to Protein Kinase Inhibitors

Share to Pyrazines

Share to Pyrazoles

Share to Translational Research, Biomedical

Source

Open in PubMed

Identifiers

PMID: 39453756
DOI: 10.1158/1078-0432.CCR-24-1867

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors.PMID 39453756Read ↗

Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging AgentsSemantic proximity Read ↗

ATR-CHK1 Axis Inhibitors in Gastric Cancer TreatmentSemantic proximity Read ↗

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid TumorsSemantic proximity Read ↗

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsSemantic proximity Read ↗

Therapeutic targeting of ATR in alveolar rhabdomyosarcomaSemantic proximity Read ↗

MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapySemantic proximity Read ↗

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSemantic proximity Read ↗

Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response RegulatorsSemantic proximity Read ↗

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal CancerSemantic proximity Read ↗

AKT1 interacts with DHX9 to Mitigate R Loop–Induced Replication Stress in Ovarian CancerSemantic proximity Read ↗

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.